Skip to main content
SpringerLink
Log in

Abaloparatide cost effective for postmenopausal osteoporosis

  • Unknown
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hiligsmann M, et al. Cost-Effectiveness of Abaloparatide for the Treatment of Postmenopausal Women with Osteoporosis. 2018 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases : abstr. OC3, 19 Apr 2018. Available from: URL: http://www.wco-iof-esceo.org/.

  2. Hiligsmann M, et al. Cost-Effectiveness of Sequential Treatment with Abaloparatide vs. Teriparatide for the Prevention of Osteoporotic Fractures in Postmenopausal Us Women at Increased Risk of Fracture. 2018 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases : abstr. P553, 19 Apr 2018. Available from: URL: http://www.wco-iof-esceo.org/.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abaloparatide cost effective for postmenopausal osteoporosis. PharmacoEcon Outcomes News 804, 4 (2018). https://doi.org/10.1007/s40274-018-4968-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-4968-1

Search

Navigation